

32nd Annual CONFERENCE

DIVANI CARAVEL HOTEL, ATHENS

10 – 11 JUNE 2026

WITH WELCOME COCKTAIL ON 9 JUNE 2026



Theodore E. Tryfon - President of PEF, CEO of ELPEN Group & Member of the Medicines for Europe's Executive Committee

Born in Mytilini, Lesvos, Theodore E. Tryfon was educated at Athens College and holds a BSc in Economics and Business Administration from the University of Southampton, followed by an MBA from City University Business School in London. He joined ELPEN in 1992 and has since played a defining role in its evolution into a vertically integrated pharmaceutical Group with a strong international presence. Today, ELPEN ranks among Greece's leading pharmaceutical manufacturers, with a turnover of €500 million (2025), exporting to over 90 countries worldwide, and a workforce exceeding 1,700 employees in Greece and abroad. The Group combines industrial scale with advanced innovation capabilities, operating four production facilities in Pikermi and Keratea (Attica), as well as the largest private Research and Experimental Centre in Spata, the Athens LifeTech Park. Internationally, ELPEN continues to expand its footprint through strategic subsidiaries, including ELPEN PHARMA GmbH in Berlin and ELPEN MEA in Dubai, strengthening its presence in key European and Middle Eastern markets. Since 2014, Mr. Tryfon has served as President of the Panhellenic Union of Pharmaceutical Industries (PEF), representing 56 pharmaceutical companies and 51 production sites across Greece. In this capacity, he has been a consistent advocate for strengthening domestic and European manufacturing, enhancing healthcare system resilience, and advancing the global competitiveness of the Greek pharmaceutical sector. At European level, his role as Executive member of Medicines for Europe places him at the center of policy discussions shaping the future of generic and value-added medicines across the European Union. Since 2029, he has contributed to the broader business community as a Member of the Board of the Hellenic Federation of Enterprises (SEV) and acting President of the Industrial Policy Committee reinforcing the critical link between industrial policy and sustainable economic development. Theodore E. Tryfon was born in Mytilini – Lesvos. He graduated from Athens College of Greece and earned his BSc in Economics and Business Administration from the University of Southampton in UK. He continued his studies by earning an MBA from City University of London Business School. In 1992 he joined Elpen Pharmaceutical Co. and presently is the Vice President and co CEO of ELPEN Group. In 2024, ELPEN Group had a turnover of 430,000,000€. Since 2023, in addition to the three productions units at Pikermi, Attikis, ELPEN also operates a new 12,000 m2 Development and Manufacturing facility in Keratea, Attikis.. Currently the Group is occupying more than 1.600 employees in Greece and abroad. ELPEN holds a leading position in the pharmaceutical market, exporting to over 90 countries and has the largest Research, Training and Experimental Center of the Greek Pharmaceutical Industry. Since 2014, Mr. Tryfon has been elected as President of the Panhellenic Union of Pharmaceutical Industries (PEF), an association which represents 49 companies with 45 production sites throughout Greece. In 2019 he became a Member of the Board of the Hellenic Federation of Enterprises (SEV) as well as a Member of the Board of Directors of Medicines for Europe, the European Association representing the European Generic and Value Added Medicines Industry.



Adrian van den Hoven - Director General, Medicines for Europe

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the Chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA). to the environment. The Dutch Ministry of VWS recognizes that medicines' residues are a burden to the environment and to the production of drinking water. The Netherlands advocates an integral approach, involving the industry sector, healthcare sector and water sector to effectively address the challenges.



Steffen Saltofte – CEO, Zentiva and President, Medicines for Europe

Steffen Saltofte is an experienced international executive with expertise in healthcare and manufacturing and a strong track record of leading complex organizations through periods of transformation. As Chief Executive Officer of Zentiva Group, one of Europe's leading manufacturers of generic, biosimilar, and value added medicines, he has guided the company through a challenging environment characterized by supply chain disruption, inflationary pressure and increasing regulatory complexity. Steffen was previously CEO of pharmaceutical company, Acino, and prior to this, held senior roles at Boehringer Ingelheim, Merial, Syngenta, and Maersk Line. With more than 5,400 employees and European production sites in the Czech Republic and Romania, Zentiva plays a critical role in supplying essential medicines to European healthcare systems. Under Steffen's leadership, the company has strengthened its focus on resilience, security of supply and operational excellence, ensuring reliable access to high quality, affordable medicines for millions of people across Europe. Steffen also serves as President of Medicines for Europe, where his main areas of focus are Health Security & European Manufacturing, Access & Affordability, Regulatory Modernization, and Sustainability & Responsibility. He engages closely with European and national institutions and policymakers, advocating for balanced frameworks that safeguard the accessibility, affordability, and availability of medicines. A purpose driven leader, Steffen is known for combining strategic clarity with a strong commitment to people and partnerships, and for fostering constructive dialogue between industry and policymakers to help strengthen Europe's healthcare systems. Steffen holds an MBA from IMD and bachelor's degrees from Copenhagen Business School and the Institute of Chartered Shipbrokers.



Julie Maréchal-Jamil - Executive Director Biosimilar medicines, Manufacturing and Supply, Medicines for Europe

Leading the Biosimilar Medicines Group, a sector group of Medicines for Europe, Julie aims at creating and nurturing dialogue with experts and partners across healthcare systems. The main objective of the Biosimilar Medicines Group is to support and facilitate the design, evolution and implementation of policies aimed at fostering greater access to biologic therapies and other healthcare products and services, with biosimilar medicines use as catalyst for smart investment and innovation in health. Since 2015, she has been actively involved, including in leadership positions, in the IGBA Biosimilars Committee activities contributing to Global policy discussions. Her knowledge and understanding of the scientific, regulatory, pharmaceutical and health policy environments at EU and global levels, greatly supports her effective engagement with all the players involved in the EU and global ecosystems. Part of the Medicines for Europe Management Team, she is responsible for People & Organisation matters, focused on employees' professional growth. With a MSc in Pharmacology, she previously worked in the pharmaceutical industry.



André Guedel - Director, Head Business Development Tax KPMG Switzerland

André is an economist and KPMG Switzerland's site selection, location development and credits, grants and incentives (CG&I) expert. He has extensive experiences in assisting regional governments and local organizations in becoming more attractive for FDI projects and he supports industrial and life sciences companies in identifying locations for their manufacturing, R+D and Share Services operations. André has a special focus on grants and incentives for manufacturing and for ESG projects in Europe. In addition to his role as KPMG Switzerland's leading Site Selection expert, André holds a senior Business Development role for KPMG Tax with focus on international business expansion. Before joining KPMG, André was heading the Swiss Federal Investment Promotion Program for North America, based in New York.



Sophie N'Gouat - Site Head and President, Sandoz Biologics France

Sophie N'Gouat is Site Head and President of Sandoz Biologics France in Toulouse. She leads large-scale biologics manufacturing operations in a global GMP environment, overseeing development, manufacturing, quality, supply chain and engineering activities. With over 20 years of experience in the biopharmaceutical industry, she has a strong track record in scaling up complex biologics production and driving industrial transformation in highly regulated settings. Her work focuses on the industrialization of biologics and the conditions required to ensure sustainable and timely patient access to these therapies. She brings a pragmatic perspective on how manufacturing capabilities, regulatory frameworks and policy decisions interact to shape competitiveness and health sovereignty in Europe.



Judit Bidló - Deputy State Secretary for Professional Healthcare Management, Ministry of Interior, Hungary

Dr. Judit Bidló has served since March 2023 as the Deputy State Secretary for the Professional Management of Healthcare at Hungary's Ministry of Interior. She is a pharmacist, economist, and infobionics engineer, and a founding member of the Hungarian Health Economics Association. Her early career included roles at Novartis and the Association of Innovative Drug Manufacturers, followed by more than a decade in drug reimbursement at the National Health Insurance Fund. She has also overseen the procurement of high priced medical devices and specialized medicinal products. Dr. Bidló continues to contribute to the National Molecular Oncoteam. Her current priorities include advancing outcome based drug financing, adapting reimbursement frameworks to telemedicine, and promoting data driven healthcare decision making.



Nikos Papandreou - Member of the European Parliament, Greece

Nikos Papandreou is a Member of the European Parliament for Greece and a member of the Group of the Progressive Alliance of Socialists and Democrats (S&D). Since first joining the European Parliament in 2023 and being re-elected in 2024, he has played an increasingly active role in shaping EU public health policy as a member of the Committee on Public Health (SANT). He is a strong advocate for a European Health Union that delivers equitable access to medicines, strengthens prevention, and reinforces Europe's health sovereignty. In the health field, Papandreou has focused on improving access, reducing inequalities in care, and strengthening Europe's pharmaceutical resilience. He has been a vocal supporter of Europe's Beating Cancer Plan, calling for greater investment in screening, early diagnosis, and modern treatments, including radioligand therapies and liquid biopsy technologies. He has consistently stressed that access to state-of-the-art diagnostics and treatments should not depend on where patients live in Europe. Papandreou has also been actively engaged in the debate on the Critical Medicines Act, framing health as a strategic pillar of European sovereignty. He has supported measures to expand European production of critical medicines and active pharmaceutical ingredients, diversify supply chains, and encourage smarter procurement tools such as multi-winner tenders. He has also championed the inclusion of patient organisations in policymaking and the integration of candidate countries into Europe's health security architecture. Before entering politics, Papandreou worked at the World Bank and served as an adviser to the Greek government. A writer and commentator as well as a policymaker, he brings a broad international perspective to his work and is committed to ensuring that Europe remains both innovative and socially just in the life sciences and healthcare sectors.



Ines Windisch - Head of Corporate Affairs & Sustainability, Zentiva Group and Co-Chair of the Sustainability Steering Committee, Medicines for Europe

Recognized as a highly experienced leader with more than 30 years in the healthcare industry, Ines has worked across Communications, Corporate Affairs, Marketing & Sales, Market Access, Human Resources, and Sustainability at local, regional, and global levels. She brings a strong focus on change management, organizational excellence, and stakeholder engagement, with a proven track record in leading successful integration and transformation projects in both start-ups and large organizations. For the past eight years, Ines has been part of the Zentiva journey. Together with 5,400 colleagues across Europe and India, Zentiva provides health and wellbeing for all generations while strengthening resilience and fostering a truly great place to work. Ines engages communities with drive, creativity, and a highly personalized communication style. She is known for building high-performing teams, strengthening corporate culture and identity, and transforming organizations from good to great. Passionate about making a positive impact on the environment and society, Ines holds an MBA in Healthcare Management and an MSc in Sustainability & Responsible Business from universities in Vienna.



Mari Amos - Advisor on Pharmaceutical Policies, Ministry of Social Affairs, Estonia

Mari Amos is a policy expert at the Estonian Ministry of Social Affairs, working on health and pharmaceutical policy with a focus on access to medicines, system sustainability, and European regulatory developments. She has an academic background in law, complemented by postgraduate studies in European studies and public health, enabling her to bridge legal, policy, and public health perspectives. In her current role, she contributes to the development and implementation of pharmaceutical policies in Estonia, including the transposition and application of European Union legislation. She has been actively involved in EU-level processes, including work linked to the Estonian Presidency of the Council of the European Union, engaging with the European Parliament on health, social, and internal market issues. Her work on medicines policy focuses in particular on the role of off-patent medicines in ensuring sustainable healthcare systems, improving affordability, and strengthening security of supply. She is engaged in policy discussions on how to create a balanced pharmaceutical framework that supports competition, resilience of supply chains, and long-term system efficiency. In parallel, she has an increasing focus on the environmental dimensions of pharmaceuticals, including the impact of manufacturing, use, and waste on the environment, and the integration of environmental considerations into pharmaceutical policy. Beyond her national role, Mari Amos has extensive international experience. She served for eight years as a member of the United Nations Subcommittee on Prevention of Torture, where she contributed to work on health-related issues in places of detention. She is currently a member of the Council of Europe's Committee for the Prevention of Torture. Her work reflects a multidisciplinary approach, combining legal, economic, and public health perspectives to advance policies that ensure access to medicines while supporting sustainability and resilience in Europe's pharmaceutical systems.



Dr. Nikolaos S. Thomaidis - Professor of Analytical Chemistry at the National and Kapodistrian University of Athens

Dr. Nikolaos S. Thomaidis, Professor of Analytical Chemistry at the National and Kapodistrian University of Athens, is specialized in Environmental and Food Chemistry. He is the member of editorial boards for two scientific journals (Analytical Methods and Global NEST Journal), guest editor of four journals (Analytica Chimica Acta, Analytical Letters, Journal of Hazardous Materials and Chemosphere) and a reviewer for 52 international journals. Prof. Thomaidis leads a dedicated scientific group, Trace Analysis and Mass Spectrometry (TrAMS) group (<http://trams.chem.uoa.gr/>) and has established a constant research activity in the last 25 years (237 papers and 15 book chapters, >7,400 citations, h-55). Moreover, Prof. Thomaidis has extensive experience in supervising and coordinating research projects with both national and European funding. The current research interest of TrAMS group is focused on the development of cutting-edge methodologies and workflows to fully characterize the molecular picture “fingerprint” of environmental samples and foodstuff, based on High Resolution Mass Spectrometric (HRMS) analysis, using both LC-ESI- and GC-APCI- QTOFMS.



Christos Gallis – Executive Vice President, STADA AG

Christos Gallis is Executive Vice President at STADA AG and member of its Global Executive Committee, responsible for Central / Eastern Europe and Eurasia. He is also currently a member of the Executive Board of Medicines for Europe. Throughout his extensive career in the pharmaceutical industry, Christos has led large and diverse teams across a wide range of geographies, steering them to deliver strong growth while “making the world a better place”. Christos holds a degree in Economics and an MBA from the University of Chicago and has strong interest in Sustainability and Public Policy.



Christine Årdal - Co-Lead Access, EU-JAMRAI-2

Christine Årdal MBA PhD works at the Norwegian Institute of Public Health. Her research focuses on the policy and governance aspects of antimicrobial access and innovation. Årdal is the co-lead of the access work package for the European Union’s Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI).



Csaba Gáli - Deputy Head of Unit, DG HERA, European Commission

Csaba Gáli is Deputy Head of Unit at the Health Emergency Preparedness and Response Authority (DG HERA), the European Commission Directorate-General responsible for medical countermeasures for health emergencies. He works in the Security of Supply, Manufacturing and Procurement Unit, where his portfolio includes policy measures to strengthen the resilience of EU supply chains and manufacturing capacity. This includes EU FAB, the EU's vaccine manufacturing capacity reservation mechanism. He is also responsible for the EU joint procurement of medical countermeasures. Earlier in his European Commission career, Csaba Gáli worked on the coordination of digital policy, consumer protection and retail policy. He holds a law degree and a Master's degree in Public Policy.



Marc Crouton - President Region Europe, Fresenius Kabi

Marc Crouton is President of the Region Europe and Board Member at Fresenius Kabi. He is an international healthcare leader with more than 30 years of experience in the pharmaceutical industry. In January 2026, he was appointed Vice President of Medicines for Europe, having been a member of the Executive Committee since December 2024, where he contributes to industry-level dialogue and advocates for sustainable access to high quality medicines. In earlier roles, Marc Crouton served as Chief Commercial Officer overseeing Europe, Latin America, the Middle East, Africa, and Asia-Pacific. He also held several senior leadership positions, including President of Fresenius Kabi France. Since May 2023, he is President Region Europe at Fresenius Kabi, with full P&L responsibility for a business generating over €2 billion in annual revenues.



Doctor David Willey MBE - Chief of the Medical Office, NATO Support & Procurement Agency (NSPA)

David Willey was commissioned into the British Army in 1995 and following graduation from Newcastle Dental School in 1997 he completed various clinical appointments with the Defence Dental Services in Germany and Cyprus. In 2000 he deployed to Sierra Leone with a UK Short Term Training Team and in 2003 to Kosovo, where he served as the Senior Dental Officer for British Forces. Following attendance at the Intermediate Command and Staff Course (Land) in 2008, he served in a policy and planning role at Army Headquarters, followed by a return to clinical practise in 2010, as a Senior Dental Officer in Germany. In 2013 he deployed to Mali with the European Union Training Mission, where he served as the principal medical planner at Mission Headquarters in Bamako. In October 2013 he returned to the Joint Services Command and Staff College as a student on the Advanced Command and Staff Course, where he also completed the MA in Defence Studies with Kings College London. Following Staff College, he was assigned to Headquarters 1st (United Kingdom) Division in 2014; then subsequently HQ 102 Logistic Brigade in February 2015, before serving as Chief of Staff HQ British Forces Germany Health Service in 2017. In 2018 he was awarded the MBE and selected for promotion to

Colonel, assuming the post of Assistant Chief of Staff Joint Medical Division and Medical Advisor at Allied Joint Force Command HQ in Brunssum. In October 2021 he was assigned to NATO HQ in the role of Liaison Officer to the Committee of the Chiefs of Military Medical Services in NATO (COMEDS), where he also served as Chair of the Military Committee Medical Standardization Board. David Willey left the British Army and took up his current position with NATO Support and Procurement Agency, in January 2025.



Athanasios Lapatinas - Senior Medicines and Medical Devices Shortages Specialist, European Medicines Agency

Athanasios Lapatinas is a Senior Medicines and Medical Devices Shortages Specialist at the European Medicines Agency (EMA), where he works on medicines shortages, supply chain vulnerabilities, and critical medicines policy. He currently supports EU-level initiatives related to the implementation of the Critical Medicines Act, the Union List of Critical Medicines, and the development of methodologies to assess vulnerabilities in supply chains of critical medicines in the Union List. Before joining EMA, he worked at the European Commission (DG HERA) as an Intelligence Analyst, leading analytical work on critical medicines supply chain vulnerabilities and contributing to the development of the Assessment of the supply chain vulnerabilities for the first tranche of the Union list of critical medicines technical report. He also co-led analytical work during the HERA/EMA pilot exercise on antibiotics shortages preparedness. Earlier in his career, he worked as an Economic Analyst at the Joint Research Centre (JRC) of the European Commission, supporting evidence-based policymaking through quantitative analysis, impact evaluation, and applied economics research. Prior to joining the European institutions, he held academic positions as Assistant Professor in Economics.



Katerina Patavou - Director of European Public Affairs, Industrial Policy and Sustainability, Panhellenic Union of Pharmaceutical Industries

Katerina Patavou, currently is the Director of European Public Affairs, Industrial Policy and Sustainability for the Panhellenic Union of Pharmaceutical Industries (PEF), a national association member of Medicines for Europe, representing 55 member companies that manufacture medicines and operate in Greece. Her role at PEF encompasses both national and European level engagement on policy developments and corporate advocacy. In 2025, she was elected Vice-Chair of the National Association Committee of Medicines for Europe. With over 12 years of European public affairs experience, policy analysis, national implementation and strategic advocacy in the healthcare sector, coupled with her legal background, she has a thorough understanding of the European legislative ecosystem. She is a graduate from the University of Reading with a bachelor degree in Law (LLB) and a Masters in EU Law from Kings College London. She finessed her business acumen during her tenure at several Brussels based consultancies after working as accredited assistant at the European Parliament.



Sonia García - Executive Adviser, Spanish Ministry of Health

Sonia García is a Health Economist and currently serves as Executive Adviser at the Directorate-General for the Common Portfolio of the National Health System and Pharmacy within the Spanish Ministry of Health, performing Deputy Director General responsibilities. Her work focuses on the formulation, positioning and implementation of pharmaceutical policies both national and European, with active participation in key. Between 2016 and 2025, she held several positions at the Spanish Agency of Medicines and Medical Devices, where she became Head of the International Affairs Division and represented Spain in the Coordination Group for Health Technology Assessment (HTA). She has also worked at the Instituto de Salud Carlos III, as well as in the pharmaceutical industry, bringing a cross-cutting perspective across regulation, evaluation, and market access.”



Dr. Ilaria Passarani – Secretary General, PGEU

Ilaria Passarani is Secretary General of PGEU, the leading organization representing Europe’s pharmacists. In this role, she sets the strategic vision for the organization, provides executive leadership, and oversees its daily operations. She manages PGEU’s relationships with the national pharmacists organizations, with the EU Institutions and stakeholders. She is member of the Board of Directors and President of EMVO, the European Medicines Verification Organization. Before joining PGEU Dr. Passarani worked as Head of the food and health Department at the European Consumer Organization BEUC. She also served as a member of the European Medicines Agency (EMA) Management Board. She graduated in Economics from Bocconi University (Italy) and holds a PhD from the Faculty of Health, Medicine and Life Sciences of the Maastricht University (The Netherlands).



Christophe Delenta – President Europe, Sandoz

Christophe Delenta was appointed President Europe and is a member of the Executive Committee effective September 1, 2024. Previously he was serving as cluster head within the Sandoz Europe region, overseeing the business in major EU markets such as France, Italy and Spain. Christophe Delenta has more than 25 years of experience as a leader in the pharmaceutical industry and has worked for other leading companies such as Sanofi and Eli Lilly before joining Sandoz in 2016 as Country Head for France. Looking back on a successful career in a broad range of commercial roles, he has worked in Europe, Africa, the United States and Latin America, for both generic and originator companies. Christophe Delenta is a member of the Executive Committee of Medicines for Europe (MfE), which represents the European generics and biosimilars industry. He regularly contributes to industry discussions and initiatives in areas such as generics and biosimilars, supply chain solutions, as well as regulatory and economic policy.

Christophe Delenta holds a pharmaceutical doctor's degree from the René Descartes University in Paris and a master's degree in marketing from the Chatenay Malabry University in Paris.



Michal Nitka - Senior Vice President Generics Head Europe & OTC Global Head, Teva

Michal Nitka is senior vice president generics head Europe & OTC global head at Teva since September 2024. Nitka has 30 years of experience in the pharmaceutical industry, including senior leadership roles at Teva and other top companies, with expertise in generics, biosimilars, EU markets, and healthcare systems. He is a medical doctor by training and holds postgraduate degrees in marketing and management from the University of Łódź, the Chartered Institute of Marketing, along with executive development programs IMD Lausanne.



Nikos Dedes - Secretary General, Greek Patient

Nikos Dedes is the President of the Association of people living with HIV/AIDS “Positive Voice” and the former President of the Greek Patients’ Association. He has a long involvement in European organizations and is a member of the Steering Committee of NEAT id (European Network for the Treatment of HIV, Hepatitis and Global Infections). He is a member of the EACS (European AIDS Clinical Society) HIV Treatment Guidelines Group, a member of the Steering Committee of the HIV Outcomes and EuroTEST initiatives and a member of the Board of the European Patients’ Forum (EPF). He has served as Chair of the European AIDS Treatment Group (EATG), a former member of the Board of the European Medicines Agency (EMA), and a former member of the WHO HIV Strategic and Technical Advisory Committee. He has advocated for many years for universal access to evidence-based and cost-effective care and prevention services for all people as a moral imperative and a prerequisite for a prosperous and just society.



Katarína Gatialová - Director, EU Government Affairs and Policy, Viatrix

PharmDr. Katarína Gatialová, EMBA, is Director of EU Government Affairs and Policy at Viatrix, the largest provider of medicines in Europe based on volume, where she leads the company’s Brussels Policy Office and oversees strategic engagement on EU pharmaceutical, trade, industrial, and health policy. She represents Viatrix in leading European and international industry platforms, including Medicines for Europe, AmCham EU, and the U.S. Chamber of Commerce, while also serving on the Board of Medicines for Europe and as Chair of its Public Affairs Committee. With a background

spanning the pharmaceutical industry, European institutions, government, and international organizations, Katarína brings extensive expertise in EU pharmaceutical legislation, critical medicines policy, global supply chains, pharmaceutical trade and regulatory strategy. She has played an active role in shaping discussions on Europe's pharmaceutical competitiveness and supply resilience, including through contributions to the European Commission's Critical Medicines Alliance and HERA Industry Cooperation Forum. Prior to joining Viatris, Katarína worked with the European Commission, the Ministry of Health of the Slovak Republic, and the International Pharmaceutical Federation. She also served as President of the European Health Parliament, leading cross-sector discussions on health innovation and policy reform. Katarína holds a Doctor of Pharmacy degree completed in Slovakia and Germany, and an Executive MBA from Vlerick Business School, with executive studies also completed in the United States and Singapore. Her research focused on the off-patent medicines sector and pharmaceutical supply resilience. She is based in Brussels.



Aris Angelis - Secretary General for Strategic Planning, Hellenic Ministry of Health, Greece

Dr Aris Angelis is Secretary General for Strategic Planning at Greek Ministry of Health, reporting to the Minister of Health. Among his responsibilities include all aspects of national pharmaceutical policy and regulation, national coverage provisions, digital health and strategic planning, as well as the coordination of the implementation of relevant actions and projects of the RRF. As part of the Ministry of Health political leadership, he represents Greece in European fora, such as the EU EPSCO Health Ministers' Council, negotiating the country's positions, including the negotiation of relevant legislative acts (e.g. the EU Pharmaceutical Package, the Critical Medicines Act, the Regulation on the European Health Data Space), whereas has also the responsibility for the implementation of relevant EU directives and regulations (e.g. the Falsified Medicines Directive, the Health Technology Assessment Regulation). Additionally, he has assumed various roles, representing Greece at EMA's Committee for Medicinal Products for Human Use (CHMP), OECD's Health Committee, WHO Novel Medicines Platform, HERA Joint Procurement Agreements and HERA Joint Industrial Cooperation Forum. Before taking on the new General Secretariat for Strategic Planning, Dr Aris Angelis was Assistant Professor of Health Economics in the Department of Health Services Research and Policy at the London School of Hygiene & Tropical Medicine (LSHTM), where he remains a Visiting Associate Professor. Before joining LSHTM, Dr Angelis was a Research Fellow and a Guest Teacher at the Department of Health Policy at the London School of Economics and Political Science (LSE). Dr Angelis received his Doctor of Philosophy (PhD) in Health Policy and Economics from the LSE. He also holds an MSc in International Health Policy from the LSE, an MSc in Biopharmacy from King's College London and a BSc in Biochemistry from Imperial College London.



Lucas Sigman - CEO Insud Pharma and Chair, IGBA CEO Advisory Committee

Lucas Sigman holds a degree in Biology from the University of Buenos Aires and an MBA from IESE Business School. With more than 20 years of experience, he leads an international group with operations in over 50 countries, 20 manufacturing facilities, and a workforce of more than 10,000 professionals. From 2014 to 2020, he served as General Manager of Chemo, Insud's business unit, where he built broad expertise across multiple areas of the pharmaceutical industry, including R&D, Manufacturing, Commercial Operations, and Portfolio Management. Since 2020, he has served as CEO of Insud Pharma. In addition to his executive responsibilities, Lucas Sigman is a regular speaker and contributor at leading industry forums. He is Chairman of the IGBA CEOs Advisory Committee, a member of the Executive Committee of Medicines for Europe, and a board member of Fundación Mundo Sano, a non-profit organization devoted to neglected diseases, with which he is actively engaged.



Mariano Genovesi - General Counsel and Intellectual Property Director, Argentine Pharmaceutical Industry Chamber (CILFA) and IGBA Vice-Chair

Mariano Genovesi is General Counsel and Intellectual Property Director at CILFA, the association representing generic and biosimilar manufacturers in Argentina, and Vice-Chair of the International Generic and Biosimilar Medicines Association. He has more than 30 years of experience in the pharmaceutical industry, with a strong focus on intellectual property, competition law, and regulatory matters in Argentina and Latin America. Mariano is a lawyer from the University of Buenos Aires (UBA) (1991) and holds a Master of Laws (LL.M.) in Intellectual Property Law with the highest honors from George Washington University Law School (Washington, DC, 2008). He is a member of the Board of Directors and President of the Parliamentary Relations Department of the Argentine Industrial Union (UIA), where he has represented the organization in negotiations on the MERCOSUR–European Union free trade agreement and in several Business 20 (B20) working groups. Mr. Genovesi has extensive litigation experience, particularly in intellectual property and competition law. He has acted as lead counsel in landmark pharmaceutical cases involving data exclusivity, the Bolar exemption, damages for abusive injunctions, and the regulatory approval of biosimilars. He previously served as Secretary General of the University of Buenos Aires (2018–2022) and has worked as a consultant for international organizations, including the Inter-American Development Bank, UNCTAD, and WIPO, as well as for governmental bodies in Argentina and Peru, focusing on technology transfer, biotechnology protection, and the implementation of intellectual property provisions in trade agreements. Mr. Genovesi is a full professor of Business Law at the University of Buenos Aires and teaches courses on industrial property, competition, and markets. He has published extensively in his field and serves as a peer reviewer for leading international journals on intellectual property and competition law.



Ana Gaunt - Secretary-General, International Generic and Biosimilar medicines Association (IGBA)

Ana Gaunt was nominated Secretary General of the International Generic and Biosimilar medicines Association (IGBA) in March 2026. Ana brings more than 20 years of experience across the generics and biosimilar medicines sectors, with a strong background in pharmaceutical policy, market access, business development, and global programme leadership. Ana began her career at Medicines for Europe, where she represented the generics industry in EU-level discussions on pricing, reimbursement, and access. In that role, Ana worked with European Commission bodies, health ministries, regulatory agencies, payers, and WHO-linked initiatives to help shape advocacy positions on behalf of association members. Subsequently, Ana held senior roles at Sandoz and Novartis further deepening Ana's operational knowledge across the value chain. This included global strategic planning, country and regional portfolio and launch leadership across 17 European markets, as well as global programme management spanning market access, health economics, and digital transformation across Europe, Asia, and the Americas. As Secretary General, Ana is committed to fostering neutrality and consensus-building across a diverse membership, and to advancing IGBA's work on regulatory harmonisation, biosimilar policy, supply chain resilience, and the contribution of generic medicines to sustainable health systems.



Maryna Slobodnichenko - Deputy Minister of Health of Ukraine for European Integration (inv)